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Summary Conflicting reports of MDR1 gene expression in human tumours are observed according to
whether studies are performed at the mRNA or P-glycoprotein level. We have investigated this expression in
22 clinically drug-resistant sarcomas at the mRNA level by Northern blot (NB), Dot blot (DB), in situ
hybridisation (ISH), and at the protein level by immunohistochemistry (IHC) using three monoclonal
antibodies (MoAbs): C219, JSB1, MRK16. Increased MDR1 mRNA expression was detected by NB, DB, and
ISH in 1/22 sarcoma (an Ewing's sarcoma). ISH was perfectly correlated with DB hybridisation and confirmed
the expression of tumoral cells alone. Specific staining of 100% of tumoral cells was obtained with the three
MoAbs in the same sarcoma. Expression in tumoral cells of 12 other sarcomas was detected with MRK16,
and positive staining of stromal cells with both C219 (1/22) and MRK16 (8/22) was observed. This study
confirms that MDR1 overexpression occurs in human sarcomas but is not the principal mechanism of
drug-resistance. Furthermore, positivity with one antibody does not necessarily imply the presence of P
glycoprotein (P-gp) and a disparity may exist between the levels of P-gp and its mRNA in the same sample. So
care must be taken in interpreting results and more sensitive techniques such as the polymerase chain reaction
(PCR) could prove useful.
The development of drug resistance in malignant tumours
limits the effectiveness of cytotoxic drugs. This is especially
true in human sarcomas which are characterised by their
frequent refractoriness to chemotherapy. This problem prob-
ably implies many mechanisms of resistance. The best
known, termed 'multidrug resistance' (MDR), is character-
ised in vitro by cross resistance to a variety of structurally
unrelated drugs following exposure to one of them. The
MDR phenotype is associated with increased expression of
the MDR human gene known as MDR1 (Roninson et al.,
1984). This gene codes for a high molecular weight mem-
brane glycoprotein of 170 kD: the P-glycoprotein (Pgp)
(Juliano & Ling, 1976). This membrane-associated protein is
thought to act as an efflux pump extruding drugs from the
cell (Safa et al., 1990).
Human MDRl expression has been studied in a variety of
normal tissues and tumours (Thiebaut et al., 1987; Goldstein
et al., 1989; Cordon Cardo et al., 1990). The literature shows
a wide variation in MDR1 expression between tumours
investigated, investigators and methods used. The most
confficting results are observed according to whether studies
are performed at the RNA or Pgp level. Therefore, we have
attempted to find an appropriate method for the clinical
evaluation of MDR1 in human sarcomas. Here we report the
study of MDR1 expression in 22 clinically drug-resistant
sarcomas, (1) at RNA level by Northern blot (NB), Dot blot
(DB) and in situ hybridisation (ISH); (2) at the protein level
by immunohistochemistry using a panel of three monoclonal
antibodies (MoAb): C219, JSBI, MRK16.
Materials and methods
Patients
Twenty-two patients with sarcoma diagnosed and treated at
the 'Fondation Bergonie' were included in this study. In
Table I tumours are listed according to histotype, location,
and prior chemotherapeutic treatment. All patients presented
clinical drug resistance; nine were analysed before and 13
after chemotherapy. The chemotherapy used was drugs in-
volved in multidrug-resistance phenotype: anthracyclines (all
cases) associated with epipodophyllotoxins (for four
patients), vinca alkaloid (for three patients), actinomycin D
(for two patients).
Tumoral tissue fragments were obtained from surgical
specimens, quickly frozen in liquid nitrogen and stored at
-80°C. Four consecutive sections of each tumour were
made, one for ISH and the other three for each MoAb. A
sample of each tumour was fixed in Bouin's fluid for histo-
pathological analysis.
Cell lines
Positive and negative controls for MDR1/P glycoprotein ex-
pression included the drug-sensitive parental cell line of a
human breast carcinoma (WT MCF7) and a 200-fold Doxo-
rubicin-resistant subline (Adr200 MCF7), kindly provided by
K.H. Cowan (National Cancer Institute Bethesda, USA)
(Batist et al., 1986).
The sensitivity of all methods used was tested on MCF7
sublines with various levels of resistance to Doxorubicin:
6-fold (Adr6 MCF7), 50-fold (Adr5O MCF7) and 100-fold
resistant (AdrlO0 MCF7). All these sublines were Pgp +.
ISH and IHC were performed on frozen cell pellet sections of
these lines.
Hybridisation probes
Two probes were used:
- A 3-kb cDNA EcoRl fragment corresponding to the 3'
end of MDR1 cDNA. This probe, termed pAdrl, was
cloned into the EcoRl-restriction site of the plasmid
pGEM3 (Fairchild et al., 1987). It was a generous gift
from K.H. Cowan.
- A 3.6-kb DNA HindIII fragment corresponding to the
actin gene. This probe, kindly provided by D. Wallitz,
was inserted into plasmid pBR322 (Moos & Gallwitz,
1983). Probes were 32P-labelled by a multiprimer labell-
ing system (Amersham) for NB and DB analysis and
35S-labelled by nick translation (BRL) for ISH.
RNA extraction, Northern (NB) and dot blot (DB) analyses
A polytron was used to pulverise 150 mg of frozen tumoral
tissue, and total cellular RNA was extracted by the acid-
guanidium-phenol-chloroform extraction method (Chomczin-
ski & Sacchi, 1987).
For NB analysis, 15 g.g of total RNA was fractionated by
electrophoresis on a denaturating 1.2% agarose/6.6% for-
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Table I Patient data and results of MDRl/PgP expression
Prior IHC
No/Age Histological type and location Chemoth.b NB/DB ISHS35 C219 JSB, MRK16
1./32 M.F.H. - Lunga Yes -/0 - 0 0 180
2./58 M.F.H. - Soft tissue
3./72 M.F.H. - Soft tissue
Yes -/0 - 0 0 180
No -/0 - 0 0 50
Ewing S. - bone
Ewing S. - bone
Ewing S. - lunga
Ewing S. - bone
Ewing S. - bone
Spindle cell S. - Soft tissue
No -/0
Yes
Yes
- /0
+/80%
No -/0
Yes -/0
Yes -/0
- 0 0 0
50 (SC)
- O O 0
50 (SC) 300 (SC)
++ 200 300 300
- 0 0 10
160(SC)
- 0 0 5
100 (SC)
- 0 0 80
10./59 Dermatofibro S. - Soft tissue
11./55 Undifferentiated S. - Soft tissue
No -/0
No -/0
- 0 0 0
- 0 0 240
R.M.S. - soft tissue
R.M.S. - lymph nodea
L.M.S. - soft tissue
L.M.S. - bowel
L.M.S. - soft tissue
LipoS. - soft tissue
LipoS. - soft tissue
19./63 Chordoid S. - bone
20./67 Chordoid S. - soft tissue
No -/0 - 0 0 20
160 (SC)
No -/0 - 0 0 0
160 (SC)
Yes -/0 - 0 0 0
Yes -/0
No -/0
Yes
Yes
- /0
- /0
Yes -/0
No -/0
- 0 0 40
100 (SC)
_ 0 0 160
0
_ 0
0
0
50(SC)
100
0
- 0 0 0
- 0 0 0
21./62 Angio S. - soft tissue
22./34 Epithelioid S. - soft tissue
Yes -/0 - 0 0 10
Yes
- /0 - 0 0 0
Abbreviations: ametatasis; MFH, malignant fibrous histiocytoma; RMS, rhabdomyosarcma; LMS, leiomyosar-
coma; SC, stromal cells. 'The chemotherapy used in treatment was in all cases anthracyclines associated with
epipodophyllotoxines (for four patients), vinca alkaloid (for three patients), actinomycin D (for two patients).
maldehyde gel and transferred to a nylon membrane
(Hybond N, Amersham) (Maniatis et al., 1982).
For DB analysis, 0.1 gIg, 0.3 fig, 1 gig of denaturated total
RNA were spotted on the nylon membrane using a BRL
Hybridot Manifold apparatus, then were fixed 5 min by UV.
Membranes were prehybridised and hybridised as described
by Maniatis et al. and exposed to X-ray films for 2-7 days at
-80°C. Hybridisation signals were quantified by densitomet-
ric scanning (Biocom). Quantification of MDR1 mRNA exp-
ression levels was performed using P actin mRNA levels as
internal standard. Results were expressed as percentages with
respect to the signal obtained with the Adr200 MCF7 cell
line.
The sensitivity of this MDRI mRNA expression analysis
was ascertained by determining MDRI mRNA expression in
Adr6, 50 and 100 MCF7 sublines. Hybridisation signals were
observed in AdrlOO and Adr5O MCF7 but not in Adr6
MCF7 sublines.
RNA in situ Hybridisation (ISH)
The method used was that of E. Normand and B. Bloch
(1992). Microscope slides bearing cells or 10pg frozen tissue
sections were fixed for 15min at 4°C in 4% paraformalde-
hyde. Slides were then prehybridised in 4 x SSC, 1 x Den-
hart, 0.1 x sarcosyl. Washes were performed in 4 x SSC. The
probe was hybridised to the cells for 12 h at 40°C in 50%
formamide, 10% Dextran sulfate, 4 x SSC, 1% sarcosyl,
1 x Denhart, 1000 gLg ml-' Salmon sperm DNA, 240 gg ml1'
Escherichia coli tRNA, 2.4 mg Na2HP04 and 200 mM DTT.
Two washes were performed, first at 25°C, then 40C, in
x SSC. After dehydration in ethanol, slides were exposed to
Kodak X-ray film for 4 days, then were dipped in Ilford K5
emulsion at 4°C for a 2-week autoradiographic exposure.
Signal specificity was ensured by a negative result on the WT
MCF7 cell line, and a positive one on the Adr200 MCF7
subline, and dose-dependent extinction of the signal by com-
petition with the same probe (pAdrl) which was biotine-
labelled by nick translation. The sensitivity of this method
was ascertained by positive results on Adr6, Adr5O and
AdrIOO MCF7 sublines (Figure 2a). The average number of
grains/cell for Adr6, Adr5O, AdrlOO, and Adr200 MCF7
sublines was respectively 1, 10, 17 and 25.
Immunohistochemistry (IHC)
A panel of three antibodies was used. Two of them recognise
distinct internal epitopes (Kartner et al., 1985, Scheper et al.,
1988): C219 (Centocor Malvern, PA) and JSB1 (Sanbio bv,
Uden, The Netherlands). The third recognises an external
epitope (Chevallier-Multon et al., 1991): MRK16 (gift from
T. Tsuruo, Cancer Chemotherapy Center, Tokyo, Japan).
Frozen sections were fixed in acetone for 5 min and stored at
-80°C. They were then immersed in chloroform for 30 min
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and washed in Tris buffer saline (TBS) plus Tween. All
sections were stained by an avidin-biotine peroxidase com-
plex technique using the LSAB kit supplied by Dako (Dako,
Trappes, France). C219, JSB1 and MRK16 MoAb were
applied at a dilution of 1/300 for the first two and at 1/1000
for the third. A negative control consisted of sections
incubated with a purified mouse IgG in place of the primary
specific antibody (Sigma). All sections were examined and
scores were established by two pathologists independently of
the clinical data. Immunostaining was semi-quantitatively
expressed as follows: the percentage of stained tumoral cells
multiplied by the intensity of immunostaining evaluated from
1 to 3 (1 = weak, 2 = moderate, 3 = strong). Sensitivity of
staining was tested on Adr6, Adr50 and AdrlOO MCF7
sublines. Positive staining of MCF7 Adr6 cells was demon-
strated with undiluted JSB1 and MRK16 MoAb, but not
with undiluted C219.
Results
Results are shown for each tumour in Table I.
MDRJ mRNA expression
MDR1 mRNA expression was detected by Dot Blot (DB)
hybridisation on RNA samples showing undegraded ribo-
somal RNA by Northern Blot (NB) analysis. Furthermore,
RNA in situ hybridisation (ISH) was performed to examine
MDR1 expression on the cellular level.
DB hybridisation made it possible to detect overexpression
of the MDR1 gene in only one of the 22 sarcomas analysed.
For this tumour, the relative MDR1 mRNA level was 80%
with respect to the Adr200 MCF7 cell line. This case was a
pulmonary metastasis of an Ewing's sarcoma, which had
been pretreated by chemotherapy and died 4 months after
diagnosis. For the other 21 patients, eight died, there were
four progressive disease, and nine complete response. Figure
1 confirms the specific detection of the 4.8 kb MDR1 mRNA
by NB in the Adr200 MCF7 cell line and the Ewing's
sarcoma, and its absence in the WT MCF7 subline. RNA
ISH, first tested on MCF7 cell lines (Figure 2a) then on the
22 sarcomas, gave similar results with positivity of the AdrR
MCF7 sublines and the same Ewing's sarcoma. Several ob-
servations can be made from the Ewing's sarcoma shown in
Figure 3. High expression of the MDR1 gene, characterised
by the average number of grains observed per cell, was
detected in 100% of the tumoral cells, but not in the stromal
or inflammatory cells. This expression was cytoplasmic and
quite homogeneous from cell to cell (Figure 3, inset). The
number of grains observed per cell in this tumour (on
average 20), compared with the Adr200 MCF7 cell line (on
average 25), seemed to correlate perfectly with DB hybridisa-
tion results. No detectable MDR1 mRNA expression was
found in the other 21 sarcomas.
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Figure 1 a, Specific detection of the 4,8 Kb MDR1 on RNA by
NB in the Adr 200 MCF7 cell line and the Ewing's sarcoma
(Case no. 6). b, The agarose gel coloured with ethidium bromide
showing the quality of ribosomic RNA's 28S and 18S.
occurred in another Ewing's sarcoma (case 5), but only
stromal cells (50%) showed positive staining. The stromal
cells stained were spindle-shaped with elongated nuclei. No
macrophages or inflammatory cells expressed P-gp.
Discussion
P glycoprotein expression
For the three antibodies (C219, JSB1, MRK16), the
feasibility of immunohistochemical analysis was first
confirmed on the various MCF7 cell lines. Figure 2b shows
the staining results with JSBI MoAb in these various sub-
lines. Specific, homogenous, strong (= 3) staining of 100% of
tumoral cells with the 3 MoAb was obtained only in the
same Ewing's sarcoma (Figure 4). For both C219 and
MRK16 MoAbs, positive staining was observed in other
sarcomas, but JSBI MoAb gave no staining with the other
sarcomas. For the MRK16 MoAb an exclusive positive stain-
ing of tumoral cells was observed in 12 other sarcomas: five
cases with 80 to 100% (Figure 5a), three cases with 20 to
50% and four cases with 5 to 10% of the cells showing
intense reactivity (moderate: 2 to strong: 3). However, stain-
ing of stromal cells was also demonstrated with the MRK16
MoAb in 8 sarcomas without staining of tumoral cells in 4/8
tumours (Figure 5b). For the C219 MoAb, immunostaining
This study demonstrates a strong correlation between Dot
blot and RNA in situ hybridisation methods, using the same
probe (pAdrl) for evaluation of MDRl mRNA expression.
Such a correlation has previously been described (Shen et al.,
1988; Bates et al., 1991). However, sensitivity of ISH seems
better than DB hybridisation since a detection threshold of
MDR1 mRNA levels was obtained for the Adr6 MCF7 cell
line with ISH, and for the Adr5O MCF7 subline with DB.
The sensitivity of our ISH method is in agreement with
previous reports showing MDR1 mRNA detection using
RNA probes in breast cancer (KB-8-5) (Shen et al., 1988)
and neuroblastoma (SH-SY5Y) (Bates et al., 1991) cell lines,
respectively 3-fold and 4- to 6-fold resistant to Doxorubicin.
The greatest value of RNA ISH is in determining MDR1
RNA expression on a cellular level and for confirming
specific expression in tumoral but not stromal or
inflammatory cells. We did not observe any heterogeneity of
MDR1 expression by ISH in these sarcomas. This rules out
the negative results of the DB hybridisation method being1224 B. VERGIER et al.
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Figure 2 In situ hybridisation analysis of MDRl mRNA expression in the MCF7 cell lines (light field microscopy, magnification
x 400). 1. WT MCF7 (number of grains/cell = 0). 2. Adr6 MCF7 (average number of grains/cell = 1). 3. Adr5O MCF7 (average
number of grains/cell = 10). 4. Adr200 MCF7 (average number of grains/cell = 25). b, JSB1 immunoreactivity in frozen cell pellet
sections of the MCF7 cell lines (magnification x 160). WT MCF7 (1), Adr6 MCF7 (2), Adr5O MCF7 (3), Adr200 MCF7
(4).
related to scattered islets of cells expressing the MDRl gene.
However, very low levels of MDRI expression were not
detected by these two methods. Hence, more sensitive tech-
niques like the Polymerase chain reaction (PCR) could be
useful. Noonan et al. (1990) evaluated MDRI expression on
more than 300 specimens of which 92 were sarcomas (40 soft
tissue sarcomas and six Ewing's) with the PCR technique.
They showed that low to moderate levels of MDRI mRNA
could be detected in 70/92 with PCR and not by slot- blot
analysis. For these authors the PCR technique could detect
MDR1 expression in samples from cells 1-fold resistant to
Doxorubicin (KB3.1). However, in view of the sensitivity of
this technique, it would be ofpractical value only if its results
were correlated with clinical resistance.
In comparison to the above techniques, immunohisto-
chemistry offers the advantage of being a simple quick
method for processing routine specimens. Many investigators
have used this technique alone to evaluate MDR1 expression
(Thiebaut et al., 1987; Sugawara et al., 1988; Cordon Cardo
et al., 1990; Schlaifer et al., 1990; Van der Valk et al., 1990)..
However, in a number of our cases, the three antibodies gave
different staining results. In particular, MRK16 MoAb
differed from the other two MoAbs. Twelve of our 22 sar-
comas were stained only by MRK16 MoAb and did not
express MDR1 mRNA by DB or ISH, as was the case with
the leiomyosarcoma in Van der Valk's study. Moreover, a
surprising finding was the demonstration of P gp
immunoreactivity in stromal cells of one case with C219
MoAb and 8 cases with MRK16 MoAb. This immunostain-
ing pattern has already been reported by Wishart et al.
(1990) on stromal cells of breast carcinoma, and by Schlaifer
et al. on stromal cells and macrophages of various tumours
and particularly lymphomas. On the other hand, such a
pattern was not observed using JSB1 MoAb in the literature
or in our study. These facts raise a fundamental question: is
immunohistochemistry (particularly with MRK16 MoAb)
more sensitive or less specific than detection of MDR1
mRNA expression? In the opinion of Van der Valk et al.,
cross-reactions with proteins other than P-gp could explain
these positive staining results. In our study, the lack of signal
in the stromal cells after ISH supports such a hypothesis.
Furthermore, we have observed similar cross-reactivities in
various other human tumours (data not shown). For Van der
Valk et al., it is preferable to use a small panel of anti P-gp
antibodies and to consider a specimen as P-gp positive if it
reacts with all the antibodies. In the absence of available
specific antibodies, we feel it is necessary first to use a
combination of antibodies directed at different epitopes of
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Figure 3 Detection of MDR1 mRNA by in situ hybridisation on
case no. 6 (Ewing's sarcoma). Expression of MDR1 gene was
detected only on tumoral cells (arrow) and not in the stromal
cells (arrowhead) (x 160). Inset, this expression was cytoplasmic
and quite homogeneous (x 400).
the P-gp, and then to confirm positive results with a method
such as ISH which detects MDR1 mRNA expression.
At present there are only six reports reporting MDR1
expression in human sarcomas, and findings are conflicting
(Gerlach et al., 1987; Goldstein et al., 1989; Chan et al.,
1990; Tawa et al., 1990; Schlaifer et al., 1990; Toffoli et al.,
1992). Three of these six reports study P-gp expression only
by Western blotting or immunohistochemistry (Gerlach et
al., 1987; Chan et al., 1990; Schlaifer et al., 1990), and three
study MDR1 mRNA expression only by slot or dot blot
hybridisation (Goldstein et al., 1989; Tawa et al., 1990;
Toffoli et al., 1992). Our results do not agree with the
findings of these other authors: they observed a more fre-
quent overexpression of the MDR1 gene in the tumour
samples they studied. Table II summarises these results. Even
if our DB hybridisation results were compared with those of
the most recent report (Toffoli et al., 1992), important dis-
crepancies still remain which could be explained by the fact
that we did not use the same probe nor apply the same
dilutions of total RNA samples, and did not use the same
cell line for positive control. So it is very difficult to compare
these different results, and discrepancies are obvious. It
would be advisable to study the same samples with the same
methods, and for different investigators to study simultane-
ously MDR1 mRNA/P-glycoprotein expression. However, all
investigators agree on the fact that the constitutive expression
of the MDR1 gene has no effect on the primary response in
Table II Results of MDRI/PgP expression in
literature
sarcomas in the
Figure 4 Immunostaining of tumoral cells with JSB1 MoAb in
case no. 6 (Ewing's sarcoma) (x 64).
Total number Number
Reference ofsarcomas positive Techniques use?f
Chan et al., 1990) 30 9 IHC
Gerlach et al., 1987) 25 6 WB
Goldstein et al., 1989 11 0 SB
Tanor et al., 1990 1 1 IHC
Toffoli et al., 1992 36 10 DB
Schlaifer et al., 1990 3 0 DB
Our study 22 1 DB, ISH, IHC
aIHC: immunohistochemistry. WB: Western blot. DB: Dot blot. SB:
Slot blot. ISH: in situ hybridisation.
a b
Figure 5 Unexpected immunostaining with MRK16 MoAb. a, On tumoral cells in a case of malignant fibrous histiocytoma (case
no. 1) (x 160). b, On stromal cells in a case of Ewing's sarcoma (case no. 5) (x 160).1226 B. VERGIER et al.
untreated sarcomas (Chan et al., 1990; Toffoli et al., 1992).
The acquisition of high MDR1 mRNA/P-gp expression
would be predictive of further response to chemotherapy in
the course of the disease after drug treatment. Toffoli et al.
did not observe any correlation between MDR1 mRNA
expression and histologic grade, and DNA index or repli-
cative activity in human sarcomas. In the literature, many
cases studied present clinical chemotherapy resistance with-
out high MDR1 mRNA/P-gp expression: 12/13 treated
patients in our study, 4/12 in Toffoli et al.'s report. So
neither method is sensitive enough (and PCR analysis is
advisable); or else drug resistance in sarcomas could be
mediated by mechanisms other than 'typical' multidrug resis-
tance.
Finally, this study confirms that MDRl overexpression
occurs in human sarcomas, but suggests that it is not the
principal mechanism of drug-resistance. Given the fact that
positivity with one antibody does not necessarily imply the
presence of P-gp and that a disparity may exist between the
levels of P-gp and its mRNA in the same sample, care must
be taken in interpreting results. The evaluation of MDR1
expression by more sensitive techniques such as PCR with
clinical correlation could prove useful in demonstrating the
role of MDR in human sarcomas.
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